Michael Wissmeyer

Covalent targeted radioligands potentiate radionuclide therapy

[177Lu]Lu-DOTA-TATE plus long-acting octreotide versus high‑dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2–3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study

Dosimetry-based treatment planning for molecular radiotherapy: a summary of the 2017 report from the Internal Dosimetry Task Force

90Y Time-of-flight PET/MR on a hybrid scanner following liver radioembolisation (SIRT)